Business Context and Reporting Period
This Form 8-K was filed by Signal Genetics, Inc. (not Viridian Therapeutics, Inc.) on January 9, 2017. The filing reports on a special meeting of stockholders scheduled to vote on a proposed merger with Miragen Therapeutics, Inc. and the sale of Signal's MyPRS intellectual property assets.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and transactional events rather than financial performance data.
Material Changes
- Special Meeting Date Set: A special meeting of stockholders is scheduled for February 10, 2017, at 9:00 a.m. local time in San Diego, California.
- Record Date: Stockholders of record as of the close of business on January 9, 2017, are entitled to vote.
- Transaction Scope: The vote concerns the previously announced merger with Miragen and the divestiture of MyPRS assets.
Guidance, Outlook, and Risks
- Regulatory Status: Signal has filed a registration statement on Form S-4 (including a proxy statement/prospectus), but it has not yet become effective.
- Investor Warning: Investors are urged to read the proxy statement and other SEC filings before making voting or investment decisions.
- Legal Disclaimer: This communication does not constitute an offer to sell or a solicitation of an offer to buy securities.
- Participants: Directors and executive officers of both Signal and Miragen are deemed participants in the proxy solicitation.
Key Facts for Investor Verification
- Verify the final terms of the merger and asset sale in the Form S-4 proxy statement/prospectus once it becomes effective.
- Confirm stockholder eligibility based on the January 9, 2017, record date.
- Review the special interests of directors and executive officers in the merger as detailed in the proxy materials.
- Note the discrepancy between the requested company name (Viridian Therapeutics) and the actual registrant (Signal Genetics).